Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 16/20 | 0.80 |
| ▸ | MMP13 | P45452 | 12/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.55 |
| ▸ | MMP3 | P08254 | 4/20 | 0.55 |
| ▸ | MMP1 | P03956 | 3/20 | 0.55 |
| ▸ | MMP7 | P09237 | 3/20 | 0.55 |
| ▸ | MMP9 | P14780 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689670 | 1.00 | ADAMTS4 (0.80) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL12808878 | 0.83 | MMP2 (0.76) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL689562 | 0.80 | ADAMTS4 (0.80) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL689561 | 0.80 | ADAMTS4 (0.80) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL8283227 | 0.80 | ADAMTS4 (0.76) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL1656188 | 0.80 | ADAMTS4 (0.76) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL1656951 | 0.80 | ADAMTS4 (0.59) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL12730397 | 0.80 | ADAMTS4 (0.59) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL3607214 | 0.80 | MMP2 (0.75) | ADAMTS4MMP13MMP2MMP3MMP1 | |
| SCHEMBL1110930 | 0.80 | MMP2 (0.75) | ADAMTS4MMP13MMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | ADAMTS4 29/4885MMP13 5/4885MMP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.